Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Voyager Therapeutics (VYGR) Payables (2016 - 2025)

Voyager Therapeutics (VYGR) has disclosed Payables for 11 consecutive years, with $5.0 million as the latest value for Q4 2025.

  • Quarterly Payables rose 25.45% to $5.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $5.0 million through Dec 2025, up 25.45% year-over-year, with the annual reading at $5.0 million for FY2025, 25.45% up from the prior year.
  • Payables hit $5.0 million in Q4 2025 for Voyager Therapeutics, up from $2.1 million in the prior quarter.
  • In the past five years, Payables ranged from a high of $7.6 million in Q1 2024 to a low of $574000.0 in Q4 2021.
  • Historically, Payables has averaged $2.5 million across 5 years, with a median of $2.3 million in 2022.
  • Biggest five-year swings in Payables: crashed 82.52% in 2021 and later skyrocketed 347.04% in 2022.
  • Year by year, Payables stood at $574000.0 in 2021, then surged by 347.04% to $2.6 million in 2022, then tumbled by 37.49% to $1.6 million in 2023, then soared by 149.13% to $4.0 million in 2024, then grew by 25.45% to $5.0 million in 2025.
  • Business Quant data shows Payables for VYGR at $5.0 million in Q4 2025, $2.1 million in Q3 2025, and $1.8 million in Q2 2025.